Trulance to face familiar rivals in new indication

25 January 2018
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration (FDA) has approved Trulance (plecanatide) in irritable bowel syndrome with constipation (IBS-C) in adults.

This is the second indication for Synergy Pharmaceuticals’ (Nasdaq: SGYP) Trulance, which is already approved for the treatment of adults with chronic idiopathic constipation (CIC).

Trulance competes in the CIC space with medicines including Takeda Pharmaceutical’s (TYO: 4502) Amitiza (lubiprostone) and Allergan’s (NYSE: AGN) Linzess (linaclotide), and it will again be in competition with these drugs in IBS-C.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology